Deficient drug transporter function of bone marrow-localized and leukemic plasma cells in multiple myeloma

Blood

Volumn 90, Issue 9, 1997, Pages 3751-3759

  Pilarski, Linda M ^a,b   Szczepek, Agnieszka J ^a   Belch, Andrew R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CD11B ANTIGEN; CD19 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CYCLOSPORIN A; DOXORUBICIN; GLYCOPROTEIN P; MONOCLONAL ANTIBODY; PARAPROTEIN; RHODAMINE 123;

ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG TRANSPORT; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL;

EID: 0030736702     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.9.3751     Document Type: Article

References (42)

1. Durie BGM, Salmon SS: Staging, kinetics, and flow cytometry of multiple myeloma, in Wiernik P, Canellos G, Kyle R, Schiffer C (eds): Neoplastic Diseases of the Blood, vol 2. New York, NY, Churchill Livingstone, 1985, p 513
2. Greipp PR: Advances in the diagnosis and management of myeloma. Sem Hematol 29:24, 1992
3. Belch A, Shelley W, Bergsagel D, Wilson K, Klimo P, Willan A: A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding myeloma patients. Br J Cancer 57:94, 1988
4. Barlogie B, Epstein J, Selvanayagam P, Alexanian R: Plasma cell myeloma-New biological insights and advances in therapy. Blood 73:865, 1989
5. Palmer M, Belch A, Hanson J, Brox L: Reassessment of the relationship between M-protein decrement and survival in multiple myeloma. Br J Cancer 59:110, 1989
6. Bergsagel DE: Treatment of plasma cell myeloma. Ann Rev Med 30:431, 1979
7. + cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ rearrangements. Blood 89:1824, 1997
8. 8;. Pilarski LM, Masellis Smith A, Szczepek A, Mant MJ, Belch AR: Circulating clonotypic B cells in the biology of myeloma. Speculations on the origin of multiple myeloma. Leuk Lymphoma 22:375, 1996
9. + monoclonal B lineage cells in peripheral blood from myeloma patients as late stage B cells. Blood 78:711, 1991
10. + peripheral blood cells expressing CD38, CD56 and monotypic immunoglobulin light chain. Blood 85:436, 1995
11. Pilarski LM, Jensen GS: Monoclonal circulating B cells in multiple myeloma: A continuously differentiating possibly invasive population as defined by expression of CD45 isoforms and adhesion molecules. Hematol/Oncol Clin North Am 6:297, 1992
12. Masellis-Smith A, Belch AR, Mant MJ, Turley EA, Pilarski LM: Hyaluronan-dependent motility of B cells and leukemic plasma cells but not of bone marrow plasma cells in multiple myeloma: Alternate usage of RHAMM and CD44. Blood 87:1891, 1996
13. Kubagawa H, Vogler LB, Capra JD, Conrad ME, Lawton AR, Cooper MD: Studies on the clonal origin of multiple myeloma. J Exp Med 150:792, 1979
14. Billaduau D, Ahmann G, Greipp P, van Ness B: The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 178:1023, 1993
15. Bakkus MHC, van Riet I, Van Camp B, Thielemann K: Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br J Haematol 87:68, 1994
16. Corradini P, Voena C, Astolfi M, Ladetto M, Tarella C, Boccadoro M, Pileri A: High dose sequential chemotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 85:1596, 1995
17. Masellis Smith A, Belch AR, Mant MJ, Pilarski LM: Adhesion of multiple myeloma peripheral blood B cells to bone marrow fibroblasts: A requirement for CD44 and α4β7. Cancer Res 57:930, 1997
18. 17a. Szczepek AJ, Seeberger K, Wisniak J, Mant MJ, Belch AR, Pilarski LM: A high frequency of circulating B cells share clonotypic IgH CDR3 rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single cell and in situ RT-PCR. (submitted)
19. - diploid B cells in the blood of patients with multiple myeloma, (submitted)
20. 18a. Pilarski LM, Belch AJ: Circulating monoclonal B cells expressing p-glycoprotein may be a reservoir of multidrug resistant disease in multiple myeloma. Blood 83:724, 1994
21. Pilarski LM, Mant MM, Belch AR: Circulating, monoclonal, multi-drug resistant B cells may comprise the malignant stem cells population in multiple myeloma, in Dammaco F, Barlogie B (eds): Challenges in Modern Medicine, vol 4. Rome, Italy, Ares Sereno Publications, 1994, p 31
22. Pilarski LM, Szczepek A, MacDonald H, Mant MJ, Belch AR: Single cell IgH CDR3 and in situ RT-PCR for IgH CDR3 and Ig light chain unequivocally confirm that circulating CD19+ cells in multiple myeloma are B cells. Blood 86:58a, 1995 (abstr. suppl 1)
23. 20a. Pilarski LM, Yatscoff RW, Murphy GF, Belch AR: Cyclosporin A analogues and their metabolites as chemosensitizers in multiple myeloma, (submitted)
24. Pilarski LM, Belch AR: Intrinsic expression of the multidrug transporter, P-glycoprotein 170, in multiple myeloma: Implications for treatment. Leuk Lymphoma 17:367, 1995
25. Abbaszadegan MR, Futscher BW, Klimecki WT, List A, Dalton WS: Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res 54:4676, 1994
26. Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski J, Weinstein RS, Scheper RJ, Dalton WS: P-glycoprotein expression in human plasma cell myeloma: Correlation with prior chemotherapy. Blood 81:490, 1993
27. Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnen M, Roe DJ, Miller TP: Multidrug-resistant myeloma: Laboratory and clinical effects of verapamil as a chemosensitizer. Blood 78:44, 1991
28. Durie BGM, Dalton WS: Reversal of drug-resistance in multiple myeloma with verapamil. Br J Haematol 68:203, 1988
29. Sonneveld P, Durie BGM, Lokhorst HM, Marie J-P, Solbu G, Suciu S, Zittroun R, Lowenberg B, Nooter K: Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340:255, 1992
30. Sonneveld P, Durie BGM, Lokhorst HM, Frutiger Y, Schoester M, Vela EE: Analysis of multidrug resistance (mdr-1) glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma. Br J Haematol 83:63, 1993
31. Sonneveld P, Schoester M, de Leeuw K: Clinical modulation of multidrug resistance in multiple myeloma: Effects of cyclosporine on resistant tumor cells. J Clin Oncol 12:1584, 1994
32. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M: Subpopulations of normal peripheral blood and bone marrow cells express a funcrional multidrug resistant phenotype. Blood 80:2729, 1992
33. Klimecki WT, Futscher BW, Grogan TM, Dalton WS: P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 83:2451, 1994
34. Pilarski, LM, Cass CE, Tsuruo T, Belch AR: Multidrug resistance of a continuously differentiating monoclonal B lineage in the blood and bone marrow of patients with multiple myeloma. Curr Top Microbiol Immunol 182:177, 1992
35. Zola H, Mcardle PJ, Bradford T, Weedon H, Yasui H, Kurosawa Y: Preparation and characterization of achimeric CD19 monoclonal antibody. Immunol Cell Biol 69:411, 1991
36. Pietersz GA, Li WJ, Sutton VR, Burgess J, McKenzie IFC, Zola H, Trapani JA: In vitro and in vivo antitumor-activity of a chimeric anti-CD19 antibody. Cancer Immunol Immunother 41:53, 1995
37. Pilarski LM, Paine D, McElhaney JM, Cass CE, Belch AR: The multidrug transporter, p-glycoprotein 170, on normal human lymphocytes and thymocytes: Modulation with differentiation stage and during ageing. Am J Hematol 49:323, 1995
38. Jensen GS, Belch AR, Kherani F, Mant MJ, Ruether BA, Pilarski LM: Restricted expression of immunoglobulin light chain mRNA and of the adhesion molecule GD11b on circulating monoclonal B lineage cells in peripheral blood of myeloma patients. Scand J Immunol 36:843, 1992
39. Kyle RA, Greipp PR: Monoclonal gammopathies of undetermined significance, in Wiernik PH, Canellos GP, Kyle RA, Schiffer CA (eds): Neoplastic Diseases of the Blood, vol 2. New York, NY, Churchill Livingstone, 1985, p 653
40. Chaudhary PM, Mechetner EB, Roninson IB: Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 80:2735, 1992
41. Gill DR, Hyde SC, Higgins CF, Valverde MA, Mintenig GM, Sepulveda FV: Separation of drug transport and chloride channel functions of the human multidrug resistance P-glycoprotein. Cell 71:23, 1992
42. Abraham EH, Prat AG, Gerweck L, Seneveratne T, Arceci RJ, Kramer R, Guidotti G, Cantiello HF: The multidrug resistance (mdr1) gene product functions as an ATP channel. Proc Natl Acad Sci USA 90:312, 1993